Search - tctmd.com

Displaying 21 - 40 of 43

Sort: Relevancy | Date

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

L.A. McKeown

November 15, 2021

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

News Features

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

Michael O'Riordan

December 02, 2020

News Daily News

GATEWAY at 3 Years: Bariatric Surgery Continues to Reduce Need for Antihypertensive Drugs

L.A. McKeown

August 31, 2020

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

‘Striking’ Improvements in Acute MI Care Over Past 20 Years, Report Shows

Michael O'Riordan

March 19, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Daily News

Roughly Half of Obese Patients Who Have Bariatric Surgery Are Off Type 2 Diabetes Meds at 6 Years

Michael O'Riordan

February 19, 2018

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Michael O'Riordan

September 29, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

Advertisement

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

GATEWAY at 3 Years: Bariatric Surgery Continues to Reduce Need for Antihypertensive Drugs

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

‘Striking’ Improvements in Acute MI Care Over Past 20 Years, Report Shows

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Roughly Half of Obese Patients Who Have Bariatric Surgery Are Off Type 2 Diabetes Meds at 6 Years

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content